Active Ingredient: Doxycycline hyclate

Dosage Form; Route: Capsule; oral

Recommended Studies: Two in vivo studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: EQ 75 mg Base
   Subjects: Healthy males, and non-pregnant, non-lactating females, general population.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in vivo
   Strength: EQ 75 mg Base
   Subjects: Healthy males, and non-pregnant, non-lactating females, general population.

Analytes to measure (in appropriate biological fluid): Doxycycline in plasma

Bioequivalence based on (90% CI): Doxycycline

Waiver request of in-vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).